Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.07 USD | +0.50% | -0.17% | -1.47% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 14.95M | Capitalization | 509M |
---|---|---|---|---|---|
Net income 2024 * | -114M | Net income 2025 * | -111M | EV / Sales 2024 * | - |
Net cash position 2024 * | 218M | Net cash position 2025 * | 105M | EV / Sales 2025 * | 27.1 x |
P/E ratio 2024 * |
-3.97
x | P/E ratio 2025 * |
-5
x | Employees | 118 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.86% |
Latest transcript on KalVista Pharmaceuticals, Inc.
1 day | +0.50% | ||
1 week | -0.17% | ||
Current month | +6.34% | ||
1 month | +1.60% | ||
3 months | -18.78% | ||
6 months | +58.61% | ||
Current year | -1.47% |
Managers | Title | Age | Since |
---|---|---|---|
Ed Feener
FOU | Founder | 64 | 04-03-25 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 16-07-31 |
Paul Audhya
CTO | Chief Tech/Sci/R&D Officer | 51 | 21-05-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Brian Pereira
CHM | Chairman | 65 | 19-01-31 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 16-07-31 |
Albert Cha
BRD | Director/Board Member | 51 | 15-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 2 M€ | -.--% | ||
0.03% | 0 M€ | 0.00% | - | |
0.00% | 9 M€ | +10.70% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 12.07 | +0.50% | 306,594 |
24-05-15 | 12.01 | -3.84% | 272,288 |
24-05-14 | 12.49 | +4.08% | 235,954 |
24-05-13 | 12 | -0.66% | 206,938 |
24-05-10 | 12.08 | -0.08% | 217,954 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.47% | 507M | |
-2.34% | 91.42B | |
+3.16% | 41.08B | |
-11.10% | 34.26B | |
+53.99% | 25.27B | |
-9.41% | 12.81B | |
-12.25% | 11.6B | |
-44.00% | 11.42B | |
+5.77% | 9.16B | |
-4.91% | 8.22B |
- Stock Market
- Equities
- KALV Stock